Organic compounds -- part of the class 532-570 series inventions 08/09

20090216002 - Synthesis of hydroquinone derivatives: A method for synthesising a compound having the general formula (I) wherein R represents substituents selected independently from the group of H, F, Cl, Br, NO2, alkyl, aryl, aralkyl, alkoxy, aryloxy, aralkoxy and disubstituted amine R′ is independently selected from the group of H, F, Cl, Br, OH, NO2, alkyl,... Agent: Connolly Bove Lodge & Hutz, LLP

20090216003 - Stable and selective formation of hoogsteen-type triplexes and duplexes using twisted intercalating nucleic acids (tina) and process for the preparation of tina: The present invention describes a flexible basestacking monomer that can be incorporated into an oligonucleotide or oligonucleotide analogue, as well as triplex forming oligonucleotides comprising the flexible basestacking monomer. Triplex forming oligonucleotides of the invention are capable of binding sequence specifically to doublestranded target nucleic acids and are therefore of... Agent: Foley And Lardner LLP Suite 500

20090216004 - Protoporphyrinogen oxidase having activity of imparting resistance against acifluorfen and gene thereof: Protoporphyrinogen oxidase having an activity of imparting acifluorfen resistance and gene thereof are provided. Cyanobacterium protoporphyrinogen oxidase gene is identified by introducing a protoporphyrinogen oxidase gene of Arabidopsis into cyanobacterium, disrupting a cyanobacterium gene with a transposon, selecting a mutant strain in which protoporphyrinogen oxidase gene is disrupted, identifying the... Agent: Darby & Darby P.c.

20090216005 - Small breast epithelial mucin gene promoter: The human small breast epithelial mucin gene promoter is analyzed and regions corresponding to a minimum promoter element for breast cell-specific expression, an enhancer and a negative regulatory element are identified.... Agent: Ade & Company Inc.

20090216006 - Covalently bound polysaccharide-based chiral stationary phases and method for their preparation: The present invention relates to liquid chromatographic chiral stationary phases (CSPs) and their preparation. The CSPs are based on carbamate-derivatized polysaccharides that are covalently bound onto inorganic oxide carriers via unique linkage chemistry. The present invention also relates to methods of obtaining the said linkages, which include derivatizing and functionalizing... Agent: Qi-wei Lu

20090216007 - Microwave-assisted extraction of polysaccharide from artemisia sphaerocephala: This invention relates to a method of extracting crude polysaccharide by microwave-assisted from Artemisia sphaerocephala seed de-oiling dregs. In particular, the invention comprising: microwave-assisted extraction, enzymatic hydrolysis, dialysis et. al. It provides a technique whereby the polysaccharide can be extracted effectively, in a relatively short period of time (20-30 min)... Agent: Scully Scott Murphy & Presser, Pc

20090209744 - Antibacterial agent and therapeutic agent for johne's disease containing the same: wherein Me is a methyl group; and R1 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, a cycloalkyl group having 5 to 12 carbon atoms, or a phenyl group... Agent: Arthur G. Schaier Carmody & Torrance LLP

20090209745 - Radiographic contrasting agents and radio-opaque polymeric materials for medical devices: The present invention discloses a radiographic contrasting agent containing multiple aromatic groups, each of which is substituted with at least three halogen atoms. The radiographic contrasting agent can initiate a polymerization process. The present invention also discloses a radio-opaque polymeric material that comprises a biodegradable polymer having at least one... Agent: Philip S. Johnson Johnson & Johnson

20090209746 - Method of preparing a glycoside of a mono or diacylglycerol product from a plant material: The present invention provides a method of preparing a glycoside of a mono- or diacylglycerol product from a plant material. The method comprises the steps of: (i) optionally milling the plant material, (ii) extracting the optionally milled plant material with a first aqueous extraction solution obtaining a first liquid phase... Agent: William J. Sapone Coleman Sudol Sapone P.C.

20090209747 - Method to inhibit cell growth using oligonucleotides: Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e.g., human) an effective amount of a composition comprising one or more oligonucleotides which share at least 33% but less than 100% nucleotide sequence identity with the human telomere overhang repeat. Methods of treatment or... Agent: Howrey LLP - East

20090209748 - Oligonucleotides with alternating segments of locked and non-locked nucleotides: The present invention is directed to novel oligonucleotides with improved antisense properties. The novel oligonucleotides comprise at least one Locked Nucleic Acid (LNA) selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides. The present invention also provides a new class of pharmaceuticals which... Agent: Fish & Richardson PC

20090209749 - Plant centromere compositions: The present invention provides for the nucleic acid sequences of plant centromeres. This will permit construction of stably inherited recombinant DNA constructs and minichromosomes which can serve as vectors for the construction of transgenic plant and animal cells.... Agent: Marshall, Gerstein & Borun LLP

20090209751 - Methods and kits for extraction of dna: Methods and materials are disclosed for use in recovering a biopolymer from a solution. In particular, the invention provides methods for extraction and isolation of nucleic acids from biological materials. The nucleic acids can be separated by forming a stable complex with soluble polysaccharide polymers and magnetic particles, in the... Agent: Life Technologies Corporation C/o Intellevate

20090209750 - Organic compound synthesizer and method for synthesizing organic compounds: An organic compound synthesizer for synthesizing organic compounds contains at least one type of polymerizable repeat unit and includes a substrate for organic compound synthesis. A liquid supply unit is configured to supply a reaction liquid containing compounds necessary for the synthesis of organic compounds and a reaction liquid containing... Agent: Posz Law Group, PLC

20090209752 - Device and method for treating or cleaning sample material, in particular nucleic acids: The invention relates to a device and a method for cleaning sample material, in particular nucleic acids. The cleaning process takes place by means of centrifugal microfluidics and the invention provides a simple compact construction and a simple procedure. If necessary, the sample material is easily mixed with a solvent... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090209753 - Column packing material, column using the same, and method of separation using the same: Aimed at readily and exactly separate 8-hydroxy-2′-deoxyguanosine (8-OHdG) contained in a sample, a column packing material used for separating 8-OHdG, which contains a packing material composed of a material having a straight-chain hydrocarbon group having 6 or more and 30 or less carbon atoms as a functional group, and having... Agent: Turocy & Watson, LLP

20090209754 - Process for the preparation of capecitabine: The present application relates to an improved process for the preparation of capecitabine.... Agent: Kenyon & Kenyon LLP

20090203889 - Bivalent linkers and conjugates thereof: Bivalent linkers derived from compounds of formulae (V), (VI), and (VII), where X1 and X2 are leaving groups and the other variables are as defined in the claims, to be included in or for preparing vitamin, drug, diagnostic agent, and/or imaging agent conjugates are described.... Agent: Barnes & Thornburg LLP

20090203890 - Hepatitis c antivirals: The present invention relates to deoxyribozymes targeting and cleaving HCV RNA. More particularly, the present invention relates to deoxyribozymes and composition used for the inhibition of HCV replication and HCV-related diseases.... Agent: Choate, Hall & Stewart LLP

20090203891 - Sequence-determined dna fragments encoding cyclopropyl isomerase proteins: The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3′ termination... Agent: Fish & Richardson P.C.

20090203893 - Antisense compounds having enhanced anti-microrna activity: Antisense compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The antisense compounds exhibit enhanced anti-miRNA activity. Further provided are methods for enhancing the inhibitory activity of an antisense compound targeting a miRNA, comprising incorporating stability enhancing sugar modifications into the antisense compounds.... Agent: Woodcock Washburn LLP

20090203894 - Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and... Agent: Ropes & Gray LLP

20090203896 - Modulation of survivin expression: Compounds and compositions are provided for modulating the expression of survivin. The compounds, exemplified by those acting through an RNAi antisense mechanism of action, include double-stranded and single-stranded constructs, as well as siRNAs, canonical siRNAs, blunt-ended siRNAs and single-stranded antisense RNA compounds. Methods of using these compounds for modulation of... Agent: Eli Lilly & Company

20090203892 - Retrotransposon inhibition in therapy: RNA interference is useful in the treatment of cancerous lesions, wherein the RNA recognises a portion of at least one LINE-I repeat element.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090203895 - Sirna targeting cyclin-dependent kinase 4 (cdk4): Efficient sequence specific gene silencing for cyclin-dependent kinase 4 is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design... Agent: Kalow & Springut LLP

20090203897 - Method of using polymer embedded solid supports for small scale oligonucleotide synthesis: A method of synthesizing oligonucleotides is claimed. The method utilizes a synthesis column incorporating a filter-like porous polymer cartridge which contains derivatized Controlled Pore Glass (CPG) or cross-linked Polystyrene (PS) directly embedded into the polymer cartridge. Small-scale synthesis of oligonucleotides of a predetermined sequence may be accomplished by introducing reagents... Agent: Lanier Ford Shaver & Payne P.C.

20090203898 - Cellulose esters and their production in halogenated ionic liquids: Ionic liquids and cellulose ester compositions and processes for producing ionic liquids and cellulose esters. Cellulose esters can be produced by esterifying cellulose in a reaction medium comprising one or more halide ionic liquids and at least one binary component. Cellulose esters prepared via the methods of the present invention... Agent: Polly C. Owen

20090203900 - Production of cellulose esters in the presence of a cosolvent: Ionic liquids and cellulose ester compositions and processes for producing ionic liquids and cellulose esters. Cellulose esters can be produced by subjecting a cellulose-ionic liquid solution comprising cellulose, one or more ionic liquids, and one or more co-solvents to esterification to thereby produce an esterified medium comprising a cellulose ester.... Agent: Polly C. Owen

20090203899 - Treatment of cellulose esters: Ionic liquids and cellulose ester compositions and processes for producing ionic liquids and cellulose esters. Cellulose esters can be produced by esterifying cellulose in a reaction medium comprising one or more ionic liquids. Cellulose esters prepared via the methods of the present invention can be contacted with at least one... Agent: Polly C. Owen

20090203889 - Bivalent linkers and conjugates thereof: Bivalent linkers derived from compounds of formulae (V), (VI), and (VII), where X1 and X2 are leaving groups and the other variables are as defined in the claims, to be included in or for preparing vitamin, drug, diagnostic agent, and/or imaging agent conjugates are described.... Agent: Barnes & Thornburg LLP

20090203890 - Hepatitis c antivirals: The present invention relates to deoxyribozymes targeting and cleaving HCV RNA. More particularly, the present invention relates to deoxyribozymes and composition used for the inhibition of HCV replication and HCV-related diseases.... Agent: Choate, Hall & Stewart LLP

20090203891 - Sequence-determined dna fragments encoding cyclopropyl isomerase proteins: The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3′ termination... Agent: Fish & Richardson P.C.

20090203893 - Antisense compounds having enhanced anti-microrna activity: Antisense compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The antisense compounds exhibit enhanced anti-miRNA activity. Further provided are methods for enhancing the inhibitory activity of an antisense compound targeting a miRNA, comprising incorporating stability enhancing sugar modifications into the antisense compounds.... Agent: Woodcock Washburn LLP

20090203894 - Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and... Agent: Ropes & Gray LLP

20090203896 - Modulation of survivin expression: Compounds and compositions are provided for modulating the expression of survivin. The compounds, exemplified by those acting through an RNAi antisense mechanism of action, include double-stranded and single-stranded constructs, as well as siRNAs, canonical siRNAs, blunt-ended siRNAs and single-stranded antisense RNA compounds. Methods of using these compounds for modulation of... Agent: Eli Lilly & Company

20090203892 - Retrotransposon inhibition in therapy: RNA interference is useful in the treatment of cancerous lesions, wherein the RNA recognises a portion of at least one LINE-I repeat element.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090203895 - Sirna targeting cyclin-dependent kinase 4 (cdk4): Efficient sequence specific gene silencing for cyclin-dependent kinase 4 is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design... Agent: Kalow & Springut LLP

20090203897 - Method of using polymer embedded solid supports for small scale oligonucleotide synthesis: A method of synthesizing oligonucleotides is claimed. The method utilizes a synthesis column incorporating a filter-like porous polymer cartridge which contains derivatized Controlled Pore Glass (CPG) or cross-linked Polystyrene (PS) directly embedded into the polymer cartridge. Small-scale synthesis of oligonucleotides of a predetermined sequence may be accomplished by introducing reagents... Agent: Lanier Ford Shaver & Payne P.C.

20090203898 - Cellulose esters and their production in halogenated ionic liquids: Ionic liquids and cellulose ester compositions and processes for producing ionic liquids and cellulose esters. Cellulose esters can be produced by esterifying cellulose in a reaction medium comprising one or more halide ionic liquids and at least one binary component. Cellulose esters prepared via the methods of the present invention... Agent: Polly C. Owen

20090203900 - Production of cellulose esters in the presence of a cosolvent: Ionic liquids and cellulose ester compositions and processes for producing ionic liquids and cellulose esters. Cellulose esters can be produced by subjecting a cellulose-ionic liquid solution comprising cellulose, one or more ionic liquids, and one or more co-solvents to esterification to thereby produce an esterified medium comprising a cellulose ester.... Agent: Polly C. Owen

20090203899 - Treatment of cellulose esters: Ionic liquids and cellulose ester compositions and processes for producing ionic liquids and cellulose esters. Cellulose esters can be produced by esterifying cellulose in a reaction medium comprising one or more ionic liquids. Cellulose esters prepared via the methods of the present invention can be contacted with at least one... Agent: Polly C. Owen

20090198046 - Conversion method: A process for the preparation of water-soluble cellulose hydrolysis products, which comprises admixing cellulose with an ionic liquid in which the cellulose has at least some sollubility, said ionic liquid state at a temperature at or below 150 -C, and treating the resulting solution with an acid in the presence... Agent: Marshall, Gerstein & Borun LLP

20090198047 - 2'-modified oligonucleotides: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the... Agent: Woodcock Washburn LLP

20090198048 - Glycerose synthesis: Glycerose is prepared by partially oxidizing biodiesel-derived glycerol to provide a glycerose liquor containing glycerose and other side products of the glycerol oxidation reaction. The glycerose liquor may be combined without further isolation, purification or drying with a protein-containing fodder or fodder precursor to provide a rumen undegradable protein-containing ruminant... Agent: Iplm Group, P.A.